Arbutus Biopharma Logo
Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
January 04, 2022 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan
December 13, 2021 07:30 ET | Arbutus Biopharma Corporation
Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, becomes strategic partner to provide development, manufacturing and commercialization expertise for the mainland China, Hong...
Arbutus Biopharma Logo
Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement
December 07, 2021 07:30 ET | Arbutus Biopharma Corporation
Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks ...
Arbutus Biopharma Logo
Arbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors
November 11, 2021 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting®
November 10, 2021 16:30 ET | Arbutus Biopharma Corporation
Arbutus’ Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to 28 weeks after discontinuation of AB-729 ...
Arbutus Biopharma Logo
Arbutus to Participate at Jefferies London Healthcare Conference
November 10, 2021 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 04, 2021 07:30 ET | Arbutus Biopharma Corporation
 On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021         First patient dosed in Phase 2a clinical trial combining AB-729, Peg-IFNα-2a and nucleos(t)ide analog (“NA”) therapy ...
Arbutus Biopharma Logo
Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021
November 01, 2021 16:05 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
October 21, 2021 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Arbutus to Participate in October Investor Conferences
September 28, 2021 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...